H J Park1,2, K Sandor3, J McQueen1,3, S A Woller1,4, C I Svensson3, M Corr4, T L Yaksh1. 1. Department of Anesthesiology, University of California San Diego, USA. 2. Department of Anesthesiology and Pain Medicine, College of Medicine, The Catholic University of Korea, South Korea. 3. Department of Physiology and Pharmacology, Karolinska Institutet, Sweden. 4. Department of Medicine, University of California San Diego, USA.
Abstract
BACKGROUND: Glucose-6-phosphate isomerase and collagen type II antibody-induced arthritis models (K/BxN and CAIA, respectively) have an inflammatory and a post-inflammatory phase. Both phases display robust tactile allodynia. In previous work, inflammatory phase allodynia was reversed by gabapentin and ketorolac, whereas in late phase only gabapentin was effective. Here, we sought to determine if the effects of these two drugs during the early and late phases of the two arthritis models were observed in the conditioned place preference (CPP) paradigm, indicating a differential drug effect on the aversive state. METHODS: Male C57BL/6 mice received K/BxN serum intraperitoneally, while male BALB/c mice received collagen type II antibody cocktail intravenously. After onset of inflammation and allodynia, we assessed effects of i.p. gabapentin (100 mg/kg) or ketorolac (15 mg/kg) using a CPP paradigm: 2 days adaptation, 2 days conditioning (vehicle in morning and drug in afternoon), preference testing on day 5. RESULTS: Consistent with the effects upon allodynia, both gabapentin and ketorolac produced a preference for the drug-paired compartment in the early phase of the K/BxN model, while gabapentin, but not ketorolac, resulted in a place preference during late phase. In the CAIA model, consistent with differential effects upon allodynia, gabapentin produced a preference in the early phase and a trend in the late phase, whereas ketorolac was ineffective at either time. CONCLUSIONS: CPP validated the aversive state in the inflammatory and post-inflammatory phases of the K/BxN and CAIA arthritis models and correspondence between the anti-hyperpathic pharmacology as defined by thresholds and CPP.
BACKGROUND:Glucose-6-phosphate isomerase and collagen type II antibody-induced arthritis models (K/BxN and CAIA, respectively) have an inflammatory and a post-inflammatory phase. Both phases display robust tactile allodynia. In previous work, inflammatory phase allodynia was reversed by gabapentin and ketorolac, whereas in late phase only gabapentin was effective. Here, we sought to determine if the effects of these two drugs during the early and late phases of the two arthritis models were observed in the conditioned place preference (CPP) paradigm, indicating a differential drug effect on the aversive state. METHODS: Male C57BL/6 mice received K/BxN serum intraperitoneally, while male BALB/c mice received collagen type II antibody cocktail intravenously. After onset of inflammation and allodynia, we assessed effects of i.p. gabapentin (100 mg/kg) or ketorolac (15 mg/kg) using a CPP paradigm: 2 days adaptation, 2 days conditioning (vehicle in morning and drug in afternoon), preference testing on day 5. RESULTS: Consistent with the effects upon allodynia, both gabapentin and ketorolac produced a preference for the drug-paired compartment in the early phase of the K/BxN model, while gabapentin, but not ketorolac, resulted in a place preference during late phase. In the CAIA model, consistent with differential effects upon allodynia, gabapentin produced a preference in the early phase and a trend in the late phase, whereas ketorolac was ineffective at either time. CONCLUSIONS: CPP validated the aversive state in the inflammatory and post-inflammatory phases of the K/BxN and CAIA arthritis models and correspondence between the anti-hyperpathic pharmacology as defined by thresholds and CPP.
Authors: Christina A Christianson; Maripat Corr; Gary S Firestein; Anahita Mobargha; Tony L Yaksh; Camilla I Svensson Journal: Pain Date: 2010-08-23 Impact factor: 6.961
Authors: Jaymin Upadhyay; Christian Geber; Richard Hargreaves; Frank Birklein; David Borsook Journal: Neurosci Biobehav Rev Date: 2017-08-12 Impact factor: 8.989
Authors: Sarah A Woller; Cody Ocheltree; Stephanie Y Wong; Anthony Bui; Yuya Fujita; Gilson Gonçalves Dos Santos; Tony L Yaksh; Maripat Corr Journal: Brain Behav Immun Date: 2018-11-19 Impact factor: 7.217
Authors: Sarah A Woller; Satheesh B Ravula; Fabio C Tucci; Graham Beaton; Maripat Corr; R Rivkah Isseroff; Athena M Soulika; Marianne Chigbrow; Kelly A Eddinger; Tony L Yaksh Journal: Brain Behav Immun Date: 2016-04-01 Impact factor: 7.217
Authors: Sébastien Sannajust; Ian Imbert; Victoria Eaton; Terry Henderson; Lucy Liaw; Meghan May; Mary F Barbe; Tamara King Journal: Pain Date: 2019-09 Impact factor: 7.926
Authors: Yusuf S Althobaiti; Amal Alghorabi; Fahad S Alshehri; Bandar Baothman; Atiah H Almalki; Hashem O Alsaab; Walaa Alsanie; Ahmed Gaber; Hussam Almalki; Abdulrahman S Alghamdi; Ahmad Basfer; Sultan Althobaiti; Ana Maria Gregio Hardy; Zahoor A Shah Journal: Sci Rep Date: 2020-06-26 Impact factor: 4.379
Authors: Benjamin L Allen; Karli Montague-Cardoso; Raffaele Simeoli; Romain A Colas; Silvia Oggero; Bruno Vilar; Peter A McNaughton; Jesmond Dalli; Mauro Perretti; Emanuele Sher; Marzia Malcangio Journal: Pain Date: 2020-09-01 Impact factor: 7.926